

CITATION REPORT

List of articles citing

Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US

DOI: 10.1080/13696998.2018.1557199

Journal of Medical Economics, 2019, 22, 187-195.

Source: <https://exaly.com/paper-pdf/74531835/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
6	Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment. <i>Cancer Treatment Reviews</i> , 2020 , 90, 102107	14.4	8
5	Combination of Withaferin-A and CAPE Provides Superior Anticancer Potency: Bioinformatics and Experimental Evidence to Their Molecular Targets and Mechanism of Action. <i>Cancers</i> , 2020 , 12,	6.6	15
4	A budget impact analysis of gilteritinib for the treatment of relapsed or refractory acute myeloid leukemia in a US health plan. <i>Journal of Medical Economics</i> , 2021 , 24, 19-28	2.4	2
3	Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021 , 27, 1377-1387	1.9	
2	Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study. <i>Frontiers in Public Health</i> , 2021 , 9, 777199	6	0
1	Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials. <i>Journal of Market Access & Health Policy</i> , 2022 , 10,	3.7	0